ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO031

Galectin-3 and EGF Are the Only Cardiorenal Biomarkers to Predict AKI Progression in the Setting of Acute Heart Failure

Session Information

Category: Acute Kidney Injury

  • 102 AKI: Clinical‚ Outcomes‚ and Trials

Authors

  • Duff, Stephen, University College Dublin College of Health Sciences, Dublin, Ireland
  • Wettersten, Nicholas, VA San Diego Healthcare System, San Diego, California, United States
  • Horiuchi, Yu, Shakai Fukushi Hojin Mitsui Kinen Byoin, Chiyoda-ku, Tokyo, Japan
  • Raturi, Sagar, University College Dublin College of Health Sciences, Dublin, Ireland
  • Irwin, Ruairi, University College Dublin College of Health Sciences, Dublin, Ireland
  • Murray, Patrick T., University College Dublin College of Health Sciences, Dublin, Ireland

Group or Team Name

  • The AKINESIS Investigators
Background

Acute Kidney Injury (AKI) is common in hospitalized patients and is associated with high morbidity and mortality. Acute Kidney Injury Neutrophil gelatinase–associated lipocalin Evaluation of Symptomatic heart failure Study (AKINESIS) was a prospective, international, multicentre cohort which enrolled 927 patients presenting with acute heart failure (AHF). We hypothesised that novel urinary and plasma cardiorenal biomarkers would predict progression of AKI and associated outcomes in the setting of AHF.

Methods

The primary analysis assessed if biomarkers measured at the time of developing Stage 1 or 2 AKI within 72 hours of admission predicted progression to a higher AKI Stage, RRT or death within 30 days. Twenty-four novel urinary and plasma biomarkers were analysed using commercially available ELISAs and the architect platform.

Results

In total, 175 patients had Stage 1–2 AKI within 72 hours of hospital admission and were included in the study. Of the 24 biomarkers studied, plasma Galectin-3 and EGF improved prediction of AKI progression. None of the other biomarkers were associated with the outcome.

Conclusion

AKI progression in AHF occurred in the absence of tubular damage as assessed by a panel of urinary plasma biomarkers, consistent with the functional mechanism of AKI in AHF. Systemic inflammatory and fibrotic processes may contribute to progression.

Funding

  • Government Support – Non-U.S.